## FORM 4

#### Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations

may continue. See

Instruction 1(b).

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
OMB Number:	3235-0287					
Estimated average burden						
hours per response	0.5					

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1 Name an		s)												
1. Name and Address of Reporting Person - Gallagher Carol Giltner  (Last) (First) (Middle) C/O ATARA BIOTHERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SUITE 200  (Street)  SOUTH SAN FRANCISCO, CA 94080				2. Issuer Name and Ticker or Trading Symbol Atara Biotherapeutics, Inc. [ATRA]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
				Date of Earliest Transaction (Month/Day/Year)     01/16/2015  4. If Amendment, Date Original Filed(Month/Day/Year)							ve title below)		er (specify belo	w)
										6. Individual or Joint/Group Filing(Check Applicable Line)  X_ Form filed by One Reporting Person Form filed by More than One Reporting Person  ired, Disposed of, or Beneficially Owned				ine)
(City) (State) (Zip)			Table I - Non-Derivative Securities Acqui					s Acquire						
1.Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Year)			2A. Deemed Execution Date, if		Code (Instr.	4. Securities Acq (A) or Disposed of (Instr. 3, 4 and 5)		uired 5. Amount of of (D) Owned Follow		Securities Beneficially wing Reported		6. Ownership Form:	Beneficial Ownership	
				Cod	e V A	mount (A) or (D)	Price			\ \ \	I) Instr. 4)			
1. Title of Derivative	2.	3. Transaction		(e.g., puts, calls, wai 4. 5. Nu Transaction of Code Deriv ar) (Instr. 8) Secur Acqu (A) o Dispr (D)		rrants,	nired, Disposed of, or Bene options, convertible secur 6. Date Exercisable and Expiration Date (Month/Day/Year)		eficially O	lid OMB co	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	Ownersh Form of Derivativ Security: Direct (D or Indirects)	Beneficia Ownersh (Instr. 4)
Security (Instr. 3)			Execution Date, if	Transact Code	tion of Deri Secu Acqu (A) of Disp (D)	vative urities uired or oosed of	Expiration	Date	7. Title a Amount Underlyi Securitie (Instr. 3	of ing es	Derivative Security	Derivative Securities Beneficially Owned Following Reported Transaction(	Ownersh Form of Derivativ Security: Direct (I or Indire (s) (I)	of Indire Benefici Ownersh (Instr. 4)
Security	or Exercise Price of Derivative	Date	Execution Date, if any	Transact Code	tion of Deri Secu Acqu (A) of Disp (D)	vative urities uired or posed of r. 3, 4,	Expiration (Month/Da	Date ny/Year)  Expiration	Amount Underlyi Securitie	of ing es	Derivative Security (Instr. 5)	Derivative Securities Beneficially Owned Following Reported	Ownersh Form of Derivativ Security: Direct (I or Indire	of Indire Benefici Ownersh (Instr. 4)

#### **Reporting Owners**

Damardia - Oranga Nama / Addama	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Gallagher Carol Giltner C/O ATARA BIOTHERAPEUTICS, INC.	v					
701 GATEWAY BOULEVARD, SUITE 200 SOUTH SAN FRANCISCO, CA 94080	X					

### **Signatures**

/s/ Tina Gullotta, Attorney-in-Fact for Carol Gallagher	01/20/2015
**Signature of Reporting Person	Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option will vest 100% on January 1, 2016.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.